152 related articles for article (PubMed ID: 35884442)
1. Towards Personalized Sampling in Clear Cell Renal Cell Carcinomas.
Manini C; López-Fernández E; López JI
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884442
[TBL] [Abstract][Full Text] [Related]
2. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level.
Manini C; López-Fernández E; Lawrie CH; Laruelle A; Angulo JC; López JI
Curr Urol Rep; 2022 Jun; 23(6):93-97. PubMed ID: 35416538
[TBL] [Abstract][Full Text] [Related]
3. Detection of Intratumor Heterogeneity in Modern Pathology: A Multisite Tumor Sampling Perspective.
Cortés JM; de Petris G; López JI
Front Med (Lausanne); 2017; 4():25. PubMed ID: 28321395
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Tumor Eco-Evolution in Renal Cell Carcinoma Sampling.
López-Fernández E; López JI
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518081
[TBL] [Abstract][Full Text] [Related]
5. Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC).
Guarch R; Cortés JM; Lawrie CH; López JI
F1000Res; 2016; 5():2020. PubMed ID: 27635226
[TBL] [Abstract][Full Text] [Related]
6. Precision sampling fuels precision oncology: an evolutionary perspective.
Manini C; López-Fernández E; López JI
Trends Cancer; 2021 Nov; 7(11):978-981. PubMed ID: 34493466
[TBL] [Abstract][Full Text] [Related]
7. Multisite tumor sampling enhances the detection of intratumor heterogeneity at all different temporal stages of tumor evolution.
Erramuzpe A; Cortés JM; López JI
Virchows Arch; 2018 Feb; 472(2):187-194. PubMed ID: 28842744
[TBL] [Abstract][Full Text] [Related]
8. A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma.
Lopez JI; Cortes JM
F1000Res; 2016; 5():385. PubMed ID: 27127618
[TBL] [Abstract][Full Text] [Related]
9. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.
López JI; Pulido R; Cortés JM; Angulo JC; Lawrie CH
Pathol Res Pract; 2018 Aug; 214(8):1110-1114. PubMed ID: 29910061
[TBL] [Abstract][Full Text] [Related]
10. Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma.
López JI; Angulo JC
Curr Urol Rep; 2018 Jan; 19(1):3. PubMed ID: 29374850
[TBL] [Abstract][Full Text] [Related]
11. Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma.
Ran X; Xiao J; Zhang Y; Teng H; Cheng F; Chen H; Zhang K; Sun Z
Ther Adv Med Oncol; 2020; 12():1758835920977117. PubMed ID: 33425025
[TBL] [Abstract][Full Text] [Related]
12. High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma.
Guarch R; Lawrie CH; Larrinaga G; Angulo JC; Pulido R; López JI
Ann Diagn Pathol; 2018 Jun; 34():27-30. PubMed ID: 29661723
[TBL] [Abstract][Full Text] [Related]
13. Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma.
Laruelle A; Manini C; López JI; Rocha A
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136439
[TBL] [Abstract][Full Text] [Related]
14. Intratumor heterogeneity: A new perspective on colorectal cancer research.
Zheng Z; Yu T; Zhao X; Gao X; Zhao Y; Liu G
Cancer Med; 2020 Oct; 9(20):7637-7645. PubMed ID: 32853464
[TBL] [Abstract][Full Text] [Related]
15. Intratumor heterogeneity in clear cell renal cell carcinoma: a review for the practicing pathologist.
López JI
APMIS; 2016 Mar; 124(3):153-9. PubMed ID: 26865355
[TBL] [Abstract][Full Text] [Related]
16. Multi-Site Tumour Sampling Improves the Detection of Intra-Tumour Heterogeneity in Oral and Oropharyngeal Squamous Cell Carcinoma.
Jie W; Bai J; Yan J; Chi Y; Li BB
Front Med (Lausanne); 2021; 8():670305. PubMed ID: 34041255
[No Abstract] [Full Text] [Related]
17. Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.
Hsieh JJ; Manley BJ; Khan N; Gao J; Carlo MI; Cheng EH
Semin Cell Dev Biol; 2017 Apr; 64():98-106. PubMed ID: 27615548
[TBL] [Abstract][Full Text] [Related]
18. Discovering intratumor heterogeneity: the next frontier for pathologists.
López JI; De Petris G
Pathologica; 2017 Jun; 109(2):110-113. PubMed ID: 28748969
[TBL] [Abstract][Full Text] [Related]
19. Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma.
Bolck HA; Corrò C; Kahraman A; von Teichman A; Toussaint NC; Kuipers J; Chiovaro F; Koelzer VH; Pauli C; Moritz W; Bode PK; Rechsteiner M; Beerenwinkel N; Schraml P; Moch H
Eur Urol Focus; 2021 Jan; 7(1):152-162. PubMed ID: 31266731
[TBL] [Abstract][Full Text] [Related]
20. Snail heterogeneity in clear cell renal cell carcinoma.
Zaldumbide L; Erramuzpe A; Guarch R; Pulido R; Cortés JM; López JI
BMC Cancer; 2016 Mar; 16():194. PubMed ID: 26951092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
